The clinical expression of rheumatoid arthritis (RA) varies considerably among individual patients. Genetic variations in human leucocyte antigen (HLA) may influence clinical expression. We re-examined the association of HLA-DR with susceptibility to and clinical expression of RA using genomic tissue typing, since most studies were based on ( less reliable) serological techniques. Seventy-eight patients with recent-onset RA, all participating in a clinical trial on therapeutic strategies, were HLA-DR typed by means of low-resolution genomic typing. Cumulative disease activity within the first 3 yr of disease was measured. Of the RA patients, 54% expressed DR4 (DR4+) vs 26% of healthy controls. Rheumatoid factor (RF )-positive patients had a higher cumulative disease activity than RF-negative patients. Patients who were either DR1+ or DR4+ had a higher cumulative disease activity than those who expressed neither DR1 nor DR4. This association was less obvious after correction for RF status. The association of DR52+ (DR3, 5, 6) and a lower cumulative disease activity could also not be demonstrated after correction for RF status. Among RF-negative patients, DR51+ (or DR2+) was associated with a higher cumulative disease activity. Other HLA-DR types (including DR1 and DR4 separately) were not associated with the severity of RA. DR4 was associated with susceptibility to RA in our patients; HLA-DR low-resolution genomic tissue typing did not yield additional information to RF status for the clinical identification of individual patients with a poor prognosis.
R arthritis (RA) is an autoimmune disease that between the presence of rheumatoid factor (RF ) in which lymphocytes and macrophages are assumed and a poor prognosis [8, 9] . to play a major role. Major histocompatibility complex
The classical technique for HLA-DR typing is rough (MHC ) molecules are essential for immune recognicellular leucocyte typing. A second technique is the tion. MHC is encoded in human leucocyte antigen serological method, which may yield 10-30% incorrect (HLA) gene clusters on chromosome 6. Virtually all results when more than DR1-10 subtypes are studied autoimmune diseases studied show an association with [10] . Genomic techniques are more reliable, faster and some HLA specificity [1] .
cheaper. In addition, the resolution improves: seroloThe third hypervariable region of the HLA-DR gical typing reliably identifies DR1-10, while the lowmolecule has been associated with susceptibility to RA resolution genomic technique is able to subdivide DR2, in several racial groups [2] [3] [4] [5] . This 'shared epitope' is 3, 5 and 6 each into two splits, which are called encoded by a number of alleles: DRB1 *0101, *0102, DR11-18. The high-resolution genomic technique can *0401, *0404, *0405, *0408, *1001, *1402 [1] . As a identify many subtypes; over 22 subtypes of DR4 have marker for RA in a general population, the 'shared been found [11] . In addition, DR51, 52 and 53 genes epitope' has a specificity of 56%, a sensitivity of 95% can be identified which are located close to the DRB1 and a predictive value of 2% [1] . In spite of its genes on chromosome 6. Owing to the genomic organindication of genetic susceptibility, this 'shared epitope' ization, DR2 is associated with DR51; DR3, 5, 6 with is not a useful diagnostic test for RA. DR52; and DR4, 7, 9 with DR53 [1, 11] . Several studies report an association between the
In conclusion, most studies found an association of presence of DR4 (DR4+) and the absence of DR2 DR4+, DR1+ or the so-called shared epitope with (DR2−) and clinically severe RA ( Table I ) . However, susceptibility to RA. Results on a possible association the findings are not consistent. All studies mentioned of HLA-DR with the clinical expression of RA are in Table I concern early RA patients, like our study less consistent, which might partly be due to the population. In long-term RA patients, an association different typing techniques used. Differences in the between both DR4+ and DR1+ and severe RA is population studied may also be of importance. Since described [6, 7] . The most consistent relationship is the association between RF and the clinical severity of RA is considered proven, we corrected for RF. The MATERIALS AND METHODS (PCR-SSP) [19] . In case only a single HLA-DRB1 allele could be amplified, the alleles were assumed to Patients be present homozygously. The low-resolution genomic Since 1990, all recent-onset RA patients (disease typing was used which could identify DR1-DR18 and duration < 1 yr) seen at six rheumatological centres in DR51, 52 and 53. No distinction between subtypes of the Utrecht region of the Netherlands have been asked DR1, 4, 10, 14 could be made, consequently the 'shared to participate in a randomized trial to compare theraepitope' could not be identified. In Caucasians, the peutic strategies [12] . Of the first 100 patients, 78
RA-related subtypes of DR1 and DR4 occur more blood samples for HLA-DR typing were collected by frequently than those of DR10, DR14 and the other rheumatologists for HLA typing within the period of subtypes of DR1 and DR4 [20, 21] ; therefore, often 1 yr. All patients but two were Caucasian and all only DR1 and DR4 are studied. In our analyses, we fulfilled the 1987 ACR classification criteria for RA combined DR1 and DR4 since relationships with both [13] .
susceptibility and RA severity are described. The RF test was positive if either the qualitative Disease activity latex fixation test at a dilution of 1:1 was positive or Five parameters of disease activity according to the the Rose-Waaler test (titre Á 40 IU/ml ) was positive. OMERACT recommendations were assessed [14] .
RF status was determined at baseline. Radiological damage was assessed after 3 yr of followup, using the modified method of Sharp (range 0-448) Statistical analyses [15] . The other parameters were measured every 3
Mann-Whitney U non-parametric tests and odds months during the first 2 yr and then every 6 months. ratios (OR), with 95% confidence intervals (95% CI ), Physical disability was assessed by means of a validated were used to evaluate and estimate the differences Dutch version of the Health Assessment Questionnaire between patients with a specific HLA-DR type and (HAQ) (range 0-3) [16 ] , pain score by a horizontal clinical expression. Statistical analyses were carried out visual analogue scale of 100 mm, joint score according using the SPSS/PC + statistical package [22] . to [17] and erythrocyte sedimentation rate ( ESR) by the Westergren method RESULTS in mm/1st h. High values on all parameters indicate more disease activity. A cumulative measure within Patient characteristics Of the 78 RA patients, 62% were female. At the the first 3 yr was calculated for disability, pain, joint score and ESR using the area under the curve method start of the study, the mean age was 54 yr (.. = 14) and 73% had a positive RF test. Mean disease activity (AUC ) [18] . For each individual patient, the AUC provided a summary measure over time, i.e. cumulative scores at baseline were: a disability score of 1.3 (.. = 0.7), a pain score of 44 mm (.. = 27), a joint score disease activity, by adding up the serial scores. In the case of missing values, the time-weighted means of the of 151 (.. = 105), a radiological score of 4 (.. = 5) and ESR of 46 mm/1st h (.. = 30). These baseline previous and next measurements were taken. characteristics were comparable to those for the total population of the clinical trial (N = 439). All 78 RA HLA-DR typing HLA-DRB1 alleles were determined by the polypatients were treated according to the study protocol [12] . At baseline, 32% were randomized to receive merase chain reaction using sequence-specific primers treatment with methotrexate, 22% i.m. gold, 20% (P < 0.05). No differences were found for other DR types. hydroxychloroquine and 26% non-steroidal antiinflammatory drug (NSAID) only. In January 1996, In Table III , the associations between HLA-DR and clinical expression are shown for RF+ and RF− when HLA-DR typing was carried out, 78% received a disease-modifying anti-rheumatic drug (DMARD) patients separately. Among RF+ patients, those with either DR1, DR4 or both had a higher cumulative and 22% NSAID only. We focused on an association between HLA-DR typing and the clinical expression joint score than those without DR1 and DR4 (P < 0.05). No statistically significant differences were of RA, without correcting for treatment because medication was randomized independent of HLA-DR found for the other parameters. Among RF− patients, no association between DR1/DR4 and clinical expresstatus and groups at baseline had comparable disease activity.
sion was found; however, DR51+ was associated with a higher cumulative pain and joint score (P < 0.05). In contrast, radiological damage and cumulative ESR
HLA-DR typing
The frequency of HLA-DR types for our RA tended to be lower for DR51+ patients (not statistically significant). Other DR types were not associated with patients was compared with that for 100 healthy controls who had previously been typed in the same the clinical expression of RA in the first 3 yr, after correction for RF. We also performed multiple linear laboratory. Eight RA patients (10%) and three controls (3%) were homozygous for DR4. Forty-two RA and logistic regression analyses where appropriate (data not shown). These gave the same results: clinical patients (54%) and 26 controls (26%) had at least one DR4 allele. The percentage DR4 among RA patients expression is best predicted by RF status; HLA-DR does not have an additional predictive value, nor do was significantly higher (OR = 2.9, 95% CI = 1.7-4.9), DR13 (a split of DR6) was lower (OR = 0.2, 95%
other characteristics such as age and gender. CI = 0.1-0.5). Likewise, DR53 (associated with DR4, DISCUSSION 7, 9) was found more frequently among RA patients (OR = 2.4, 95% CI = 1.5-3.7), while DR52 (associThe objective of this study was to re-evaluate the role of HLA-DR in RA, using genomic tissue typing. ated with DR3, 5, 6) was less common (OR = 0.4, 95% CI = 0.2-0.6) compared to controls. Other
For our Dutch patients with recent-onset RA, DR4 was associated with increased susceptibility to RA; the HLA-DR frequencies (including DR1) were comparable in RA and controls. A correction for the preponsame applied for DR53 which is not surprising since DR53 is associated with DR4 (and DR7, 9). DR13 (a derance of DR4 was made by excluding DR4+ people; in this subgroup, the OR for DR1 was 1.1 (95% CI = split of DR6) and DR52 (associated with DR3, 5, 6) were associated with a lower susceptibility to RA, 0.5-2.4). The OR for the association of having either DR1, DR4 or both with RA is 2.3 (95% CI = 1.4-3.5).
which also has been reported previously [23] . In contrast to reports in the literature, DR1 and DR2 could At baseline, clinical disease activity measures were not associated with HLA-DR typing or RF status. Gender not be related to RA in our study. An association with the activity of RA was less and age at disease onset were also not related to RF status, DR4 or DR1.
obvious. Our results showed that patients with either DR1 or DR4, or both, had clinically more severe disease compared to patients without these DR types. Table II shows that RF-positive (RF+) patients had A positive RF test at baseline was closely associated with increased radiological damage after 3 yr suffered more radiological damage after 3 yr than RF-negative (RF−) patients (P < 0.01). The other (P<0.01). The frequency of DR1+ or DR4+ did not differ between RF+ and RF− patients. We studied the clinical variables also indicated that RF+ patients, as did females, exhibited higher cumulative disease activassociation between HLA-DR and clinical expression, corrected for RF status, since RF status is, in several ity, but these differences did not reach statistical significance. RF status was significantly related to DR52; studies, a confirmed predictor of severity. Results, presented in Table III , showed that among RF+ among RF+ patients, DR52 was present more often (P = 0.03). RF status and other DR types were not patients, the presence of either DR1 or DR4, or both, was associated with a higher cumulative joint score. related, e.g. in RF+ and RF− patients, respectively, 58 and 43% were typed as DR4+ (P = 0.24).
Rheumatoid factor and clinical expression after 3 yr
No associations were found with the other parameters. For RF− patients, no association between DR1/DR4 and clinical expression was found. Therefore, we con-
HLA-DR typing and clinical expression after 3 yr
Cumulative disease activity after 3 yr was not associclude that DR1/DR4 is not clearly associated with the clinical expression of RA in the first 3 yr after disease ated with DR4, nor with DR1 ( Table II ) . After correction for the preponderance of DR4, DR1+ was related onset, after correction for RF status. The association between the presence of DR51 (DR2) and a higher to more radiological damage (P = 0.03). Patients who were either DR1+ or DR4+, or both (n = 53), had pain and joint score in RF− patients is remarkable, and in contrast with the literature [9, 24] . Even more more radiological damage, a higher cumulative joint score and a higher cumulative ESR than patients who radiological damage and cumulative ESR indicated the opposite (not significant). DR52+ was associated with were both DR1− and DR4− (n = 25) (P < 0.05). DR52+ patients had lower cumulative pain scores a higher cumulative pain score; this association was §RF status and DR52 expression are significantly related. Among RF-positive patients 35% are DR52+, while among RF-negative patients 62% are DR52+: P value x2 test = 0.03. *P < 0.05; **P < 0.01. not apparent after correction for RF status. DR52 and modifier in epidemiological terms. This suggests that in RF+ patients the relationship of HLA-DR and RA RF status were significantly correlated which might explain the association in the unstratified analyses.
differs from that in RF− patients. However, in the unstratified analyses, DR1/DR4 was significantly Other DR types showed no statistically significant association with clinical expression. Since results in the related to three of the five parameters, while after stratification for RF status it was only significantly unstratified analyses differed from those in RF+ and RF− patients, RF might be regarded as an effect related to joint score. Multiple linear and logistic regression analyses yielded the same conclusion: clin-R ical expression is best predicted by RF status, and 
Although treatment was random and independent
The prognostic value of HLA DR4 and B27 antigens in of HLA-DR, response to treatment may not have been early rheumatoid arthritis. Scand J Rheumatol independent of HLA-DR. In some studies HLA-DR 1993; 22:220-4. is found to be associated with the occurrence of side-
